Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID S MORRIS

Allopathic & Osteopathic Physicians Urology

NPI
1194841452
CMS profile
99310
Location
HENDERSONVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$126,656.13

259 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 6 of 6; records 251–259 of 259 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID S MORRIS

NPI 1194841452 · CMS profile ID 99310

Allopathic & Osteopathic Physicians / Urology

HENDERSONVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–259 of 259 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194841452?year=2019&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID S MORRIS, NPI 1194841452, CMS profile ID 99310. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–259 of 259 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194841452?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DAVID S MORRIS, NPI 1194841452, CMS profile ID 99310. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–259 of 259 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194841452?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DAVID S MORRIS, NPI 1194841452, CMS profile ID 99310, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–259 of 259 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1194841452?year=2019&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

259 matching records · $126,656.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 259 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–259 of 259.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dendreon Pharmaceuticals LLC $27.2101/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703766735 CMS
Endo Pharmaceuticals Inc. $20.4601/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685059053 CMS
Amgen Inc. $34.8801/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662292191 CMS
Amgen Inc. $23.0001/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662292193 CMS
Amgen Inc. $21.4801/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662292208 CMS
Amgen Inc. $2,400.0001/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662292198 CMS
Amgen Inc. $800.0001/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662292203 CMS
Astellas Pharma US Inc $14.7801/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655700207 CMS
Janssen Biotech, Inc. $15.8701/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658605061 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $126,656.13 259
PY2020 $113,261.17 182
PY2021 $99,969.77 275
PY2022 $145,164.56 304
PY2023 $178,732.47 310
PY2024 $115,575.29 286
PY2025 $91,788.46 240

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $718,932.78 45
PY2024 Principal investigator $976,499.68 115
PY2023 Principal investigator $782,698.91 74
PY2022 Principal investigator $1,006,031.69 91
PY2021 Recipient $466.33 2
PY2021 Principal investigator $790,297.24 77
PY2020 Principal investigator $1,420,267.10 278
PY2019 Principal investigator $770,945.07 134

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $37,491.28 12/31/2025 Non-covered Recipient Entity
Urology Associates Nashville, TN
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926833
Principal investigator 1 Janssen Research & Development, LLC $11,417.00 12/29/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175396831
Principal investigator 1 Janssen Research & Development, LLC $2,819.00 12/18/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175396717
Principal investigator 1 Janssen Research & Development, LLC $108.00 12/17/2025 Non-covered Recipient Entity
Uro Associates Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175274006
Principal investigator 1 Janssen Research & Development, LLC $139.00 12/01/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175396933
Principal investigator 1 Janssen Research & Development, LLC $324.00 11/24/2025 Non-covered Recipient Entity
Uro Associates Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175273584
Principal investigator 1 Janssen Research & Development, LLC $448.00 11/21/2025 Non-covered Recipient Entity
Uro Associates Admn
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175273630
Principal investigator 1 Janssen Research & Development, LLC $44,302.00 11/14/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175396723
Principal investigator 1 Janssen Research & Development, LLC $8,144.00 11/03/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175396811
Principal investigator 1 Janssen Research & Development, LLC $3,340.00 10/06/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175396825
Principal investigator 1 Janssen Research & Development, LLC $129.00 10/02/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175396898
Principal investigator 1 Janssen Research & Development, LLC $23,345.00 09/08/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175396729
Principal investigator 1 Janssen Research & Development, LLC $2,707.00 09/08/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175396867
Principal investigator 1 PFIZER INC. $14,500.00 09/06/2025 Non-covered Recipient Entity
Urology Associates PC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228753669
Principal investigator 1 Janssen Research & Development, LLC $139.00 09/05/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175396883
Principal investigator 1 Janssen Research & Development, LLC $108.00 08/28/2025 Non-covered Recipient Entity
Uro Associates Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175273361
Principal investigator 1 Janssen Research & Development, LLC $56.00 08/18/2025 Non-covered Recipient Entity
Uro Associates Admn
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175274409
Principal investigator 1 Dendreon Pharmaceuticals LLC $31,087.50 08/12/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
PROVONE STUDY No dispute reported 06/30/2026 1247892393
Principal investigator 1 Janssen Research & Development, LLC $108.00 07/28/2025 Non-covered Recipient Entity
Uro Associates Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175273997
Principal investigator 1 Janssen Research & Development, LLC $12,008.00 07/28/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175396946
Principal investigator 1 Janssen Research & Development, LLC $3,340.00 07/07/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175396711
Principal investigator 1 Janssen Research & Development, LLC $10,986.00 07/07/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175396767
Principal investigator 1 Janssen Research & Development, LLC $108.00 06/25/2025 Non-covered Recipient Entity
Uro Associates Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175274542
Principal investigator 1 Epizyme, Inc. $2,970.00 06/20/2025 Non-covered Recipient Entity
Urology Associates, Pc
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184282066
Principal investigator 1 Janssen Research & Development, LLC $108.00 06/09/2025 Non-covered Recipient Entity
Uro Associates Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175273367
Principal investigator 1 Janssen Research & Development, LLC $8,228.00 06/06/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175396756
Principal investigator 1 Janssen Research & Development, LLC $56.00 05/16/2025 Non-covered Recipient Entity
Uro Associates Admn
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175274284
Principal investigator 1 Janssen Research & Development, LLC $3,062.00 04/28/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175396904
Principal investigator 1 Janssen Research & Development, LLC $8,098.00 04/28/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175396963
Principal investigator 1 Janssen Research & Development, LLC $108.00 04/24/2025 Non-covered Recipient Entity
Uro Associates Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175273510
Principal investigator 1 Sumitomo Pharma America, Inc. $5,705.40 04/09/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176632873
Principal investigator 1 Janssen Research & Development, LLC $42,770.00 04/07/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175396969
Principal investigator 1 Janssen Research & Development, LLC $6,680.00 04/03/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175396877
Principal investigator 1 Janssen Research & Development, LLC $977.00 03/31/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175396872
Principal investigator 1 Janssen Research & Development, LLC $864.00 03/17/2025 Non-covered Recipient Entity
Uro Associates Admn
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175273431
Principal investigator 1 Janssen Research & Development, LLC $56.00 03/13/2025 Non-covered Recipient Entity
Uro Associates Admn
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175273409
Principal investigator 1 Janssen Research & Development, LLC $7,105.00 03/07/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175396940
Principal investigator 1 Janssen Research & Development, LLC $1,730.00 03/06/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175396819
Principal investigator 1 Janssen Research & Development, LLC $23,212.00 02/10/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175396735
Principal investigator 1 Janssen Research & Development, LLC $6,272.00 02/10/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175396979
Principal investigator 1 Janssen Research & Development, LLC $112.00 02/03/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175396705
Principal investigator 1 AstraZeneca Pharmaceuticals LP $385,280.72 01/29/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES, PC
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185543476
Principal investigator 1 Sumitomo Pharma America, Inc. $1,492.50 01/29/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176624992
Principal investigator 1 Epizyme, Inc. $2,327.38 01/08/2025 Non-covered Recipient Entity
Urology Associates, Pc
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184282064
Principal investigator 1 Janssen Research & Development, LLC $4,565.00 01/02/2025 Non-covered Recipient Entity
UROLOGY ASSOCIATES PC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175396788

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 2
PY2024 Value of interest $60,383.21 2
PY2023 Amount invested $0.00 1
PY2023 Value of interest $59,200.75 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $28,579.67 1
PY2021 Amount invested $6,457.65 1
PY2021 Value of interest $34,517.47 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $71,948.28 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $30,811.10 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 SN Holdings, LLC $0.00 $153.92 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124771589
PY2024 SN Holdings, LLC $0.00 $60,229.29 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124773337
PY2023 SN Holdings, LLC $0.00 $59,200.75 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1032887399
PY2022 SN Holdings, LLC $0.00 $28,579.67 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 941609387
PY2021 SN Holdings, LLC $6,457.65 $34,517.47 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 820125237
PY2020 UroGPO LLC $0.00 $71,948.28 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 737139591
PY2019 UroGPO LLC $0.00 $30,811.10 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 690775171